Methods: We developed PBPK models for CLB, its active metabolite, N-desmethylclobazam (N-CLB), and STP in healthy adults and pediatric patients with Dravet syndrome aged two years and older. This evidence concerns the gene CLYBL and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.